BioSpectrum Asia's complete coverage of BioJapan 2026: the exclusive round-up, daily reports from the floor, and what three days in Yokohama mean for Japan's drug discovery future.
BioJapan has always been where Japan shows its science to the world. This year felt different. Over three days in Yokohama, regulators, investors, global pharma scouts and founders spoke less about what Japan has and more about what it must fix: drug loss, the slow conversion of science into companies, and the race to manufacture new modalities at scale.
Our team covered the show day by day. This page brings that work together: the daily reports, our exclusive round-up, highlights from the floor and a map of where Japan's biotech playbook is being rewritten. For readers who want the numbers behind the headlines, our Japan BioReport goes deeper.
Japan is open for trials and open for deals. We hope this coverage helps you decide where you fit in.
Follow BioJapan 2026 in the order our team filed it, from the opening sessions to the final analysis.
Opening-day report on why Japan's next chapter depends on connecting its science, capital and clinics rather than going it alone.
Day 2 · Thu 8 Oct
How Japanese start-ups are finding routes to global markets, and why overseas companies are finding reasons to come in.
Round-up · Exclusive
The full analysis: six takeaways for Japan and what the week means for the rest of Asia.
Select a takeaway to see the argument and who made it on stage.
The regulators, institutes, clusters and universities that shaped the BioJapan 2026 programme. Tap a hub, or zoom into Greater Tokyo and Kansai.
Japan approved the world's first iPS cell therapies in March 2026 and owns one of the most valuable oncology franchises in the industry. It is also a country where 86 medicines already approved in the West had not begun development at all.
GET THE REPORT →Japan leads the world in regenerative medicine and holds one of oncology's most valuable franchises. It is also a market where medicines approved in the US and Europe have passed it by. This report reads both sides of that story, and asks which one the next decade belongs to.
Japan's conditional pathway for regenerative products, what it got right, and what the model now has to prove.
The roots of drug loss, and what pricing, clinical trial and PMDA reforms are doing to reverse it.
How Japanese pharma built world-class cancer assets, and whether a new generation of ventures can follow.
What global pharma, investors and service providers see in Japan, and what it means for companies across Asia.
Written for business development and licensing leaders, investors, regulatory heads and CDMO and CRO executives with a stake in Japan.
Download the Japan BioReport →Want to partner on our Japan coverage, sponsor the Japan BioReport or request coverage of your company, event or launch? Write to our Chief Operating Officer directly.
BioJapan 2026 videos and updates
All 12 videos and updates our team shared from PACIFICO Yokohama, in one place.